Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302% below fair value
$31.59−0.17 (-0.54%)
Close on Nov 13, 2026Market cap $1.89BP/E –Yield –
Agios Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Agios Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -297.7%. For fiscal 2025 it was -873.9%, against -1166.5% the year before. The highest annual figure on record is -76.2% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -873.9% | +292.6 |
| FY2024 | Dec 31, 2024 | -1166.5% | +293.1 |
| FY2023 | Dec 31, 2023 | -1459.5% | +1272.6 |
| FY2022 | Dec 31, 2022 | -2732.1% | −2463.8 |
| FY2019 | Dec 31, 2019 | -268.2% | +115.8 |
| FY2018 | Dec 31, 2018 | -384.0% | +361.8 |
| FY2017 | Dec 31, 2017 | -745.8% | −458.3 |
| FY2016 | Dec 31, 2016 | -287.6% | −86.8 |
| FY2015 | Dec 31, 2015 | -200.8% | −118.0 |
| FY2014 | Dec 31, 2014 | -82.8% | +69.4 |
| FY2013 | Dec 31, 2013 | -152.2% | −60.6 |
| FY2012 | Dec 31, 2012 | -91.6% | −15.4 |
| FY2011 | Dec 31, 2011 | -76.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -139.3% | +768.1 |
| Q2 FY2026 | Jun 30, 2026 | -247.1% | +773.0 |
| Q1 FY2026 | Mar 31, 2026 | -530.3% | +691.6 |
| Q4 FY2025 | Dec 31, 2025 | -608.9% | +556.4 |
| Q3 FY2025 | Sep 30, 2025 | -907.4% | +239.6 |
| Q2 FY2025 | Jun 30, 2025 | -1020.1% | +208.2 |
| Q1 FY2025 | Mar 31, 2025 | -1222.0% | −97.6 |
| Q4 FY2024 | Dec 31, 2024 | -1165.3% | +330.9 |
| Q3 FY2024 | Sep 30, 2024 | -1146.9% | +216.7 |
| Q2 FY2024 | Jun 30, 2024 | -1228.3% | +167.7 |
| Q1 FY2024 | Mar 31, 2024 | -1124.3% | +491.2 |
| Q4 FY2023 | Dec 31, 2023 | -1496.2% | +804.7 |
| Q3 FY2023 | Sep 30, 2023 | -1363.7% | +1227.1 |
| Q2 FY2023 | Jun 30, 2023 | -1396.0% | +353.2 |
| Q1 FY2023 | Mar 31, 2023 | -1615.5% | +10541.4 |
| Q4 FY2022 | Dec 31, 2022 | -2301.0% | −2091.1 |
| Q3 FY2022 | Sep 30, 2022 | -2590.7% | −2359.4 |
| Q2 FY2022 | Jun 30, 2022 | -1749.2% | −1526.2 |
| Q1 FY2022 | Mar 31, 2022 | -12156.9% | −12056.9 |
| Q4 FY2020 | Dec 31, 2020 | -209.9% | +89.0 |
| Q3 FY2020 | Sep 30, 2020 | -231.3% | +187.7 |
| Q2 FY2020 | Jun 30, 2020 | -222.9% | +211.3 |
| Q1 FY2020 | Mar 31, 2020 | -99.9% | +222.6 |
| Q4 FY2019 | Dec 31, 2019 | -298.9% | +22.2 |
| Q3 FY2019 | Sep 30, 2019 | -419.1% | +233.4 |
| Q2 FY2019 | Jun 30, 2019 | -434.2% | −253.7 |
| Q1 FY2019 | Mar 31, 2019 | -322.5% | +750.4 |
| Q4 FY2018 | Dec 31, 2018 | -321.0% | +598.7 |
| Q3 FY2018 | Sep 30, 2018 | -652.5% | +43.2 |
| Q2 FY2018 | Jun 30, 2018 | -180.5% | +565.1 |
| Q1 FY2018 | Mar 31, 2018 | -1073.0% | −434.9 |
| Q4 FY2017 | Dec 31, 2017 | -919.8% | −666.3 |
| Q3 FY2017 | Sep 30, 2017 | -695.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -745.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -638.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -253.5% | – |
See a number that looks wrong?